Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
Synairgen plc (SNG.L) Results of in vitro studies
Synairgen announces results of in vitro studies showing antiviral activity of interferon-beta against key SARS-CoV-2 variants
Synairgen plc (SNG.L) Full Year Results/Significant progress continues towards a treatment for COVID-19
Preliminary results for the year ended 31 December 2020
Synairgen plc (SNG.L) Home Cohort data of SG016 Phase II trial
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
Synairgen plc (SNG.L) Inclusion in US ACTIV-2 trial
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
Synairgen plc (SNG.L) COVID-19 Clinical Programme Update
– SNG001 given Fast Track designation and IND cleared by the US FDA – Phase III trial design adapted which will expedite results – Phase III trial to commence dosing
Synairgen plc (SNG.L) Lancet Respiratory Medicine publishes Phase 2 data
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
Synairgen plc (SNG.L) Clarification Regarding COVID-19 Trial
Southampton, UK – 21 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, issues clarification with respect
Synairgen plc (SNG.L) positive results from trial of SNG001 in hospitalised COVID-19 patients
Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19